

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applica	tion of:	)	
	Zatezalo et al.	)	Art Unit: To Be Assigned
Serial No.:	10/698,047	į	ū
Filed:	October 30, 2003	) )	Examiner: To Be Assigned
For:	Fluid Injection System Providing Visual Stimuli	)	

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56 AND NOTICE OF RELATED LITIGATION UNDER 37 CFR 1.178

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement and Notice of Related Litigation are filed in accordance with 37 CFR §1.56, §1.97, §1.98 and §1.178. Applicants herewith disclose references and call to the attention of the Examiner the pending federal court litigations relating to U.S. Patent No. 6,339,718 ("the '718 patent") and U.S. Patent No. 6,643,537 ("the '537 patent"), the patents to which this application claims priority, that may be deemed to be relevant to the patentability of the above-identified application.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on September 6,2005.

William L. Warren – Reg. No. 36,714

Serial No.: 10/698,047

Filing Date: October 30, 2003

IDS & Notice of Litigation

Applicants respectfully submit that the references and any litigation related documents and/or materials are made of record to assist the Examiner in the examination of the above-identified The Examiner is respectfully requested to fully consider the items and to application.

independently ascertain their teachings and relevance to this application.

I. References Cited in Corresponding Applications

The references listed on the attached Form PTO-1449 have been disclosed and/or made of record in the prosecution of the '718 patent and its related patents/applications, including U.S. Patent No. 6,643,537 ("the '537 patent"), a continuation-in-part of the '718 patent; U.S. Application Serial No. 09/941,224 ("the '224 application"), a continuation application of the '718 patent, U.S. Application Serial No. 10/309,413 ("the 413 application"), a continuation-in-

part of the '537 patent, and a Reissue Application Serial No. 10/757,348 ("the '348 reissue

application). Copies thereof may be found in the corresponding application files.

The citations of these references do not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicants may have under

applicable statutes, Rules of Practice in patent cases, or otherwise.

II. Notice of Pending Litigations Related to the '718 and the '537 patents: MPEP 2001.06 (c)

1. Medrad, Inc. v. Tyco Healthcare Group, LP, et al., Civil Case No. 01-1997-DEC, U.S.D.C.

(W.D. Penn.) ("the Pennsylvania litigation")

Applicants had notified the Patent Office about this Pennsylvania litigation related to the

'718 patent during the prosecutions of the '537 patent, the '224 application, the '413 application

and the '348 reissue application. The litigation documents exchanged by Medrad and Tyco and

Nemoto in this Pennsylvania litigation were provided to the Examiner during the prosecutions of

these patent applications. Therefore, copies thereof may be found in the corresponding

application files, if the Examiner desires.

Tyco Healthcare Group LP, et al. v. Medrad, Inc., Civil Case No. 04-773, U.S.D.C. (S.D.

Ohio) ("the Ohio litigation")

AO 1358481.1

Serial No.: 10/698,047 Filing Date: October 30, 2003 IDS & Notice of Litigation

Applicants hereby notify the Examiner that the '718 patent and the '537 patent" have also been involved in the Ohio litigation instituted by Tyco Healthcare Group LP ("Tyco"), Mallinckrodt Inc. ("Mallinckrodt") and Liebel-Flarsheim Company ("L-F"), against Medrad for Declaratory Judgment. This Ohio litigation was filed in the United States District Court for the Southern District of Ohio on November 15, 2004, under Civil Case No. 04-773.

In the Ohio litigation, Tyco et al. alleged that the '718 and the '537 patents are invalid, unenforceable and the claims of the '718 and the '537 patents are not infringed (See Tyco et al.'s Complaint of November 15, 2004). The litigation documents cited in the attached Forms 1449 have been disclosed and/or made of record in the related pending Applications: the '224 application, the 413 application and the '348 reissue application, and copies thereof may be found in the corresponding application files.

- 1) Tyco et al.'s Complaint for Declaratory Judgment and Jury Demand dated November 15, 2004;
  - 2) Medrad's Answer and Counterclaims filed December 28, 2004;
  - 3) Tyco's Reply to Defendant's Counterclaims filed January 20, 2005;
  - 4) Tyco's First Set of Interrogatories Nos. 1-8 to Defendant filed February 7, 2005;
- 5) Tyco's First Set of Requests for Production of Documents to Defendant filed February 7, 2005;
- 6) Medrad's Responses and objections to Plaintiffs' First Set of Requests for Production of Documents to Defendant filed March 11, 2005;
- 7) Medrad's Responses to Plaintiffs' First Set of Interrogatories Nos. 1-8 to Defendant filed March 11, 2005;
- 8) Medrad's First Set of Requests for Production of Documents and Things to Plaintiffs filed March 18, 2005;
- 9) Medrad's First Request for Entry Upon Land and Inspection of Things Thereon to Plaintiffs filed March 18, 2005;

Serial No.: 10/698,047 Filing Date: October 30, 2003 IDS & Notice of Litigation

10) Medrad's Consent Motion to Amend Answer and Counterclaims filed March 24, 2005;

- 11) Medrad's Amended Answer and Counterclaims filed March 24, 2005;
- 12) Medrad's First Set of Interrogatories (Nos. 1-9) filed March 24, 2005;
- 13) Tyco's Reply to Defendant's Amended Counterclaims filed April 27, 2005;
- 14) Tyco's Response to Medrad's First Set of Requests for Production of Documents and Things filed May 20, 2005; and
- 15) Tyco's Response to Medrad's First Set of Interrogatories (Nos. 1-9) field May 26, 2005.

In Medrad's Answer and Counterclaims to Tyco's Complaint, and later, in Medrad's Amended Answer and Counterclaims to Tyco's Complaint, Medrad modified the "Facts" section of its Counterclaims by referring to U.S. Patent No. 6,743,205 ("the '205 patent), adding a Third Counterclaims alleging infringement of the '205 patent, and modifying Medrad's Prayer for Relief. Validity and infringement allegations relating to the '718 and the '537 patents are also set forth in the Amended Answer and the First and Second Counterclaims. However, in Tyco's Reply to Medrad's Counterclaims and Amended Counterclaims, Tyco et al. denied the infringement allegations of Medrad's Counterclaims relating to the '718 patent and the '537 patent, respectively.

In Medrad's Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-8), Medrad objected that the interrogatory was premature in that limited discovery has been done. Medrad further asserted that Medrad's investigation of infringement by Tyco et al. is ongoing but alleged that Plaintiffs' OptiVantage<sup>TM</sup> DH injection system literally infringes at least claims 24 and 27 in the '718 patent (pages 7-8) and claims 6, 19 and 22 in the '537 patent (pages 4-7). In Medrad's Responses and Objections to Plaintiffs' First Set of Requests for Production of Documents and Things, Medrad objected to each request as being duplicative, overbroad, and not reasonably calculated to lead to the discovery of admissible evidence (General Objections on page 1; and Responses to each Request).

Serial No.: 10/698,047 Filing Date: October 30, 2003

IDS & Notice of Litigation

In Tyco's Responses to Medrad's First Set of Requests for Production of Documents and Things, Tyco simply objected each Request to the extent that 1) each Request sought the production of documents or things that are protected by the attorney-client and/or work product privileges; 2) the Requests sought information unrelated to any claim or defense in this action and is likely to lead to the discovery of admissible evidence; and/or 3) the Requests were overly broad and burdensome. In Plaintiffs' Responses to Medrad's First Set of Interrogatories (Nos. 1-9), non-infringement allegations relating to the '718 patent and the '537 patent are set forth on page 6 (Response to Interrogatory No. 5) with references to the preliminary non-infringement chart attached as Exhibit A. Unpatentability and invalidity allegations, and unenforceability due to inequitable conduct allegations relating to the '718 patent and the '537 patent are set forth on pages 6-8 (Response to Interrogatory No. 6); pages 8-9 (Response to Interrogatory No. 7); and pages 9-21 (Response to Interrogatory No. 8). Note that information relating to the '718 patent and the '537 patent of alleged prior art, Nemoto Sonic Shot 50 MR injector, the Medrad MR Spectris Injector, the Injektron 82 MRT 1.4 manual, U.S. Patent No. 5,472,403 to Cornacchia, and U.S. Patent No. 5,806,519 to Evans, III were disclosed in numerous documents submitted with the Information Disclosure Statement, and were also considered by the Patent Office during the prosecutions of the '718 patent and the '537 patent, respective (See, for example, IDS submitted on November 1, 2000; First Office Action dated December 18, 2000; and IDS submitted on May 17, 2001 during the prosecution of the '718 patent; see also, for example, IDS and Notice of Related Litigation submitted on May 19, 2003, and IDS submitted on May 29. 2003 during the prosecution of the '537 patent).

Applicants believe that certain of the alleged prior art references are not or may not be prior art to the application, and therefore reserve the right to assert that one or more of the references is not prior art to this application. Moreover, Applicants believe they can successfully swear behind many, if not all, of the Section 102 (a) and (e) references based on prior conception and/or reduction to practice.

Nevertheless, Applicants would like the Examiner to at least initially consider the subject matter disclosed in the relevant references vis-à-vis the pending claims because Applicants believe the claims will define over the references.

Serial No.: 10/698,047

Filing Date: October 30, 2003 IDS & Notice of Litigation

The Examiner is encouraged to call the undersigned attorney at 404-853-8081 if doing so will facilitate prosecution of the application. No fees are believed to be due at this time. However, the commissioner is hereby authorized to charge any additional fees due or credit any overpayment to Deposit Account 19-5029 (Ref. 23578-0009).

Respectfully submitted,

William L. Warren

Reg. No. 36,714

SUTHERLAND ASBILL & BRENNAN LLP

999 Peachtree Street, NE Atlanta, Georgia 30309-3996

Phone: 404.853.8000 Fax: 404.853.8806

Attorney Docket No.: 23578-0009

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

4

1.

	Complete if Known	
Application Number	10/698,047	
Filing Date	October 30, 2003	
First Named Inventor	Zatezalo et al.	
Art Unit	To Be Assigned	
Examiner Name	To Be Assigned	
Attorney Docket Number	23578.0009	

Examiner	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines
Initials*		Number-Kind Code <sup>2 (if known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
	A1	US-3,888,239	06/10/75	Rubinstein	
	A2	US-4,006,736	02/08/77	Kranys, et al.	
	A3	US-4,553,958	11/19/85	LeCocq	
	A4	US-4,677,980	07/07/87	Reilly, et al.	
	A5	US-4,710,166	12/01/87	Thompson, et al.	
	A6	US-5,304,126	04/19/94	Epstein, et al.	
	A7	US-5,383,858	01/24/95	Reilly, et al.	
	A8	US-5,472,403	12/05/95	Cornacchia, et al.	
	A9	US-5,494,036	02/27/96	Uber III, et al.	
	A10	US-5,553,619	09/1996	Prince	
	A11	US-5,573,515	11/1996	Wilson	
	A12	US-5,779,649	09/01/98	Prince	
	A13	US-5,782,805	07/21/98	Meinzer, et al.	
	A14	US-5,806,519	09/15/98	Evans III, et al.	
	A15	US-6,442,418	08/27/02	Evan III, et al.	

		FC	DREIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Patent Document Number  Country Code <sup>3-</sup> Number <sup>4-</sup> Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sub>6</sub>
	B1	Europe 0 192 786	09/03/86			
	B2	Europe 0 302 752	02/08/89			
	B3	WIPO 01/08730	02/08/01			

Examiner		Date	
Signature		Considered	

\*EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. The office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form. call 1-800-PTO-9199 (1-800-786-9199) and select option 2. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/698,047	
INFO	RMATION D	ISCLOS	SURE	Filing Date	October 30, 2003	
	TEMENT BY			First Named Inventor	Zatezalo et al.	ï
				Art Unit	To Be Assigned	
(Use as many sheets as necessary)				Examiner Name	To Be Assigned	
Sheet	2	of	4	Attorney Docket Number	23578.0009	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	International Search Report for Counterpart PCT Application No. PCT/US00/20770	
	C2	MCT/MCT Plus Operation Manual, pages 5-1 to 5-9 and 7-1 to 7-15, (1991); KMP 810P, Rev. B	
	C3	Medrad Spectris MR Injector Operation Manual; pages 2-1 to 2-18, 4-1 to 4-8 and 6-1 to 6-10 (1996); 92901-T-107, Rev. E.	
	C4	Medrad Envision CT Injector Operation Manual; pages 2-1 to 2-36 and 4-1 to 4-13 (1995); 92401-T-123, Rev. E.	
	C5	Medrad Vistron CT Injection System Operation Manual; pages 21-26 (2000); 95403-T-141, Rev. B.	
	C6	Optistar MR Injector System 510(k) Summary (11/4/1998).	
	C7	Optistar MR Contrast Delivery System Brochure (2000).	
	C8	Optistar MR Digital Injection System Operator's Manual, 801900-A (November 1999).	
	C9	MR Sonic Shot 50 Operator's Manual (with Accompanying English Translation of Chapter 11), Ver. 2.0.0 (December 24, 1999).	
	C10	Injektron 82 MRT User Instructions, Version MR2 (March 10, 1999).	
	C11	Injektron 82 MRT User Instructions, Version MR 1.4 (October 1997).	
	C12	English Translation of Injektron & MRT User Instructions, Version MR 1.4 (October 1997).	
	C13	Injektron 82 MRT Operating Instructions, MR 1.4 Version (October 1997).	
	C14	English Translatin of Injektron & MRT Operating Instructions, MR 1.4 Version (October 1997).	
	C15	E-Z-EM, Inc.; PercuPump II Touch*Screen CT Injector System; Manual and Operations Guide; 1996	<u> </u>
	C16	Liebel-Flarsheim Company CT 9000 Digital Injection System Operator's Manual; 800850 Rev F; Nov. 1995	
			<u> </u>
			ļ _
			-
			1

Examiner	Date	
Signature	Considered	
1		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.14. This collection of information is required by 37 CFR 1.14. This collection is estimated by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take complete, including gathering preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for fo	rm 1449/PTO			Complete if Known			
				Application Number	10/698,047		
INFO	DRMATION	DISCLO	SURE	Filing Date	October 30, 2003		
	TEMENT B			First Named Inventor	Zatezalo et al.		
				Art Unit	To Be Assigned		
(Use as many sheets as necessary)				Examiner Name	To Be Assigned		
Sheet	3	of	4	Attorney Docket Number	23578.0009		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	C17	Tyco Healthcare Group LP et al. v. Medrad, Inc., Civil Case No. 04-773, U.S.D.C. (S.D. Ohio):	T
	C18	Tyco's Complaint for Declaratory Judgment and Jury Demand, Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (November 15, 2004)	T
	C19	Medrad's Answer and Counterclaims, Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (December 28, 2004).	Ī
	C20	Tyco's Plaintiffs' Reply to Defendant's Counterclaims, Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (January 20, 2005).	T
	C21	Tyco's First Set of Interrogatories Nos. 1-8 to Defendant, Civil Case No. 04773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (February 7, 2005).	Ī
	C22	Tyco's First Set of Requests for Production of Documents to Defendant, Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (February 7, 2005).	Ī
	C23	Medrad's Responses and Objections to Plaintiffs' First Set of Requests for Production of Documents to Defendant, Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (March 11, 2005).	Ī
	C24	Medrad's Response to Plaintiffs' First Set of Interrogatories (Nos. 1-8) to Defendant, Civil Action No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (March 11, 2005).	Ī
	C25	Medrad's First Set of Requests for Production of Documents and Things to Plaintiffs, Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (March 18, 2005).	Ī
	C26	Medrad's First Request for Entry Upon Land and Inspection of Things Thereon to Plaintiffs, Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (March 18, 2005).	Ī
	C27	Medrad's Consent Motion to Amend Answer and Counterclaims, Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (March 24, 2005).	Ī
	C28	Medrad's Amended Answer and Counterclaims, Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. March 24, 2005).	T
	C29	Medrad's First Set of Interrogatories (Nos. 1-9), Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (March 24, 2005).	Ī
	C30	Tyco's Reply to Defendant's Amended Counterclaims, Civil Case No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (April 27, 2005).	T
	C31	Tyco's Response to Medrad' First Set of Requests for Production of Documents and Things, Civil Action No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (May 20, 2005).	T
-	C32	Tyco's Response to Medrad's First Set of Interrogatories (Nos. 1-9), Civil Action No. 04-773, Tyco Healthcare Group LP et al. v. Medrad, Inc. (May 26, 2005).	T

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to

<sup>\*</sup>EXAMINEN: Initial if reference considered, whether of the disposition is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is applicant:

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known			
				Application Number	10/698,047		
INFO	RMATION	DISCLO	SURF	Filing Date	October 30, 2003		
-	TEMENT B			First Named Inventor	Zatezalo et al.		
			-	Art Unit	To Be Assigned		
	(Use as many sheets as necessary)			Examiner Name	To Be Assigned		
Sheet	4	of	4	Attorney Docket Number	23578.0009		

		NON PATENT LITERATURE DOCUMENTS
Examiner nitials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
-	C33	Medrad, Inc. v. Tyco Healthcare Group, LP et al., Civil Case No. 01-1997-DEZ, U.S.D.C. (W.D. Penn.).
	C34	Medrad's Amended Complaint, Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (January 15, 2002)
-	C35	Tyco's Answer and Counterclaim to Amended Complaint, Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (January 28, 2002).
	C36	Tyco's Response to Medrad's Frst Set of Interrogatories (Nos. 1-5), Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (March 18, 2002).
	C37	Tyco's Supplemental Response to Medrad's First Set of Interrogatories (Nos. 1-5), Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (April 25, 2002).
	C38	Tyco's Response to Medrad's Fourth Request for Production of Documents and Things, Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (June 24, 2002).
	C39	Medrad's Second Amended Complaint, Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (March 26, 2002).
	C40	Tyco's Answer and Counterclaim to Second Amended Complaint, Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (July 8, 2002).
	C41	Medrad's Answer to Defendants' Counterclaim, Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (July 31, 2002).
	C42	Medrad's Amended Answer for Defendants' Counterclaim Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (August 9, 2002).
	C43	Tyco's Preliminary Prior Art and Invalidity Chart as Applied to Claims of U.S. Patent No. 6,339,718 in Response to Interrogatory Nos. 2 and 3 (Spectris) (22 pages), Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (undated).
	C44	Tyco's Prior Art and Invalidity Chart Claims of U.S. Patent No. 6.339,718 in Response to Interrogatory Nos. 2 and 3 (Nemoto Sonic Shot) (13 pages), Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (undated).
•	C45	Alleged Nemoto Operators' Manual (labeled MAL-P17-004295 to MAL-P17-004315).
	C46	Tyco's Preliminary Noninfringement Chart of U.S. PatentNo. 6,339,718 in Response to Interrogatory No. 7, Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (undated).
****	C47	Nemoto's Responses to Medrad's First Requests for Admissions (Nos. 1-25), Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (December 2, 2002).
	C48	Tyco's Responses to Medrad's First Set of Requests for Admissions Nos. 1-37, Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (January 13, 2003).
	C49	Tyco's Second Supplemental Response to Medrad's First Set of Interrogatories (Nos. 1-5), Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (January 15, 2003).
_	C50	Photograph of Nemoto's Sonic Shot 50 MR Injector (labeled NEMOTO-012162) (undated).
	C51	Alleged Nemoto Instruction Manual for Sonic Shot 50 MR Injector (labeled NEMOTO-012137 to 012161) (undated).
	C52	Alleged Nemoto Instruction Manual for Sonic Shot 50 MR Injector (labeled NEMOTO-001989 to NEMOTO-0120800) (Japanese and English)
	C53	Update, Clinical Imagiology, Vol. 4, No. 6 (June 1993) (labeled NEMOTO-012081 to NEMOTO-012089).
1.00	C54	Tyco's Response to Medrad's Fourth Set of Request for Admissions (Nos. 54-79), Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (March 31, 2003).
	C55	Covenant, Civil Action No. 01-1997-DEZ, Medrad, Inc. v. Tyco Healthcare Group LP, et al. (August 11, 2003).

Examiner	Date	
Signature	Considered	ļ
l *	Į.	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending not the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for deciding this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form call 1.800-PTO-9199 (1-800-786-9199) and select option 2.